SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 27, 2001
PharmaNetics, Inc.
--------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
North Carolina
--------------------------------------------------------------------------------
(State or other jurisdiction of incorporation)
0-25133 56-2098302
-------------------------------- ----------------------------
(Commission file Number) (IRS Employer ID Number)
9401 Globe Center Drive, Morrisville, North Carolina 27560
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 919-582-2600
--------------
5301 Departure Drive, Raleigh, North Carolina 27616
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 5. Other Events.
------------
On April 23, 2001, the Registrant entered into a Stock Purchase
Agreement and an Amended and Restated Distribution Agreement with Bayer
Corporation. On April 24, 2001, the Registrant issued a press release about
those transactions. The Agreements and the press release are attached as
Exhibits.
Item 7. Exhibits
(c) Exhibits
Exhibit No.
10.27 Common Stock Purchase Agreement between the Registrant and
Bayer Corporation dated April 23, 2001.
10.28 Amended and Restated Distribution Agreement between Registrant
and Bayer Corporation dated April 23, 2001.
99.1 Press Release dated April 24, 2001.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PHARMANETICS, INC.
Date: April 27, 2001 /s/ John P. Funkhouser
------------------------------------------
John P. Funkhouser
President and Chief Executive Officer
3